[go: up one dir, main page]

US7608740B2 - Method of synthesizing key intermediates for the production of camptothecin derivatives - Google Patents

Method of synthesizing key intermediates for the production of camptothecin derivatives Download PDF

Info

Publication number
US7608740B2
US7608740B2 US11/997,688 US99768805A US7608740B2 US 7608740 B2 US7608740 B2 US 7608740B2 US 99768805 A US99768805 A US 99768805A US 7608740 B2 US7608740 B2 US 7608740B2
Authority
US
United States
Prior art keywords
compound
process according
camptothecin
mixture
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US11/997,688
Other languages
English (en)
Other versions
US20080221358A1 (en
Inventor
Ramakrishna Rao
Venkata Rama Rao Alla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avra Laboratories Pvt Ltd
Original Assignee
Avra Laboratories Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avra Laboratories Pvt Ltd filed Critical Avra Laboratories Pvt Ltd
Assigned to AVRA LABORATORIES PVT. LTD. reassignment AVRA LABORATORIES PVT. LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ALLA, RAO VENKATA RAMA, RAO, RAMAKRISHNA
Publication of US20080221358A1 publication Critical patent/US20080221358A1/en
Application granted granted Critical
Publication of US7608740B2 publication Critical patent/US7608740B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C221/00Preparation of compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/06Preparation of nitro compounds
    • C07C201/08Preparation of nitro compounds by substitution of hydrogen atoms by nitro groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/06Preparation of nitro compounds
    • C07C201/12Preparation of nitro compounds by reactions not involving the formation of nitro groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/45Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/36Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring increasing the number of carbon atoms by reactions with formation of hydroxy groups, which may occur via intermediates being derivatives of hydroxy, e.g. O-metal
    • C07C29/38Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring increasing the number of carbon atoms by reactions with formation of hydroxy groups, which may occur via intermediates being derivatives of hydroxy, e.g. O-metal by reaction with aldehydes or ketones
    • C07C29/40Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring increasing the number of carbon atoms by reactions with formation of hydroxy groups, which may occur via intermediates being derivatives of hydroxy, e.g. O-metal by reaction with aldehydes or ketones with compounds containing carbon-to-metal bonds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/30Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation with halogen containing compounds, e.g. hypohalogenation
    • C07C45/305Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation with halogen containing compounds, e.g. hypohalogenation with halogenochromate reagents, e.g. pyridinium chlorochromate
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings

Definitions

  • the present invention relates to a process for preparation of 2-amino-5-hydroxypropiophenone, a key intermediate for the synthesis of camptothecin analogs including 7-Ethyl-10-hydroxycamptothecin and novel intermediates thereof.
  • Camptothecin (herein referred as CPT) a natural alkaloid isolated from the bark of Camptotheca acuminata is known to possess antitumor activity by inhibition of nucleic acid synthesis. Due to some severe side effects of this natural compound, various camptothecin derivatives have been synthesized with reduced toxicity and enhanced antitumor activity.
  • One such compound is 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin hydrochloride trihydrate (Generic name: irinotecan; herein referred to as CPT-11).
  • Camptothecin analogs such as CPT-11 and others are derived by a chemical synthesis from CPT, which is obtained from plant sources.
  • CPT which is obtained from plant sources.
  • the amount of CPT obtained from natural plant source is extremely low and the purity of the final CPT-11 is also low ( ⁇ 97%) due to the contamination of related natural products.
  • the demand for CPT-11 is increasing and the supply of CPT is gradually reducing.
  • camptothecin and camptothecin analogs are known in the art. These synthetic methods include (i) methods in which naturally occurring camptothecin is synthetically modified to produce a number of analogs and (ii) totally synthetic methods.
  • Patent Application no. US2004/0106830 A1 discloses the preparation of AB ring (2-amino-5-hydroxycamptothecin) for CPT-11 synthesis starting from either 5-hydroxy-2-nitrobenzaldehyde or from 5-benzyloxy-2-nitrobenzaldehyde as shown in the scheme 2
  • the objective of the present invention is to provide a suitable method of producing 2-amino-5-hydroxypropiophenone (herein referred to as compound 11) corresponding to AB ring (part of camptothecin from readily available 3-halobenzaldehyde.
  • compound 11 2-amino-5-hydroxypropiophenone
  • AB ring part of camptothecin from readily available 3-halobenzaldehyde.
  • the reactions are simple to perform and have practical utility.
  • the present invention discloses a process for efficient production of 2-amino-5-hydroxypropiophenone corresponding to the AB ring part of camptothecin (CPT) skeleton, which is a key intermediate useful for the total synthesis of camptothecin analogs such as SN-38 and CPT-11.
  • CPT camptothecin
  • the present invention discloses a process for preparation of 2-amino-5-hydroxypropiophenone (11) which comprises;
  • 2-amino-5-hydroxypropiophenone is made starting from 3-halobenzaldehyde by a simple and commercially feasible approach.
  • the method can be adopted to synthesize 2-amino-5-hydroxy phenyl alkyl ketones.
  • the alkyl group can be 1 to 6 carbons, and if required, can be extended either linear or branched alkyl chain.
  • step 1 compound (13) is obtained by reacting a 3-halobenzaldehyde (12) preferably 3-Fluorobenzaldehyde with a Grignard reagent in an inert atmosphere.
  • a Grignard reagent is prepared by reacting ethyl halide with magnesium in tetrahydrofuran (referred as THF) or solvent ether.
  • THF tetrahydrofuran
  • solvent ether solvent ether
  • reaction solution is quenched with saturated aqueous ammonium chloride solution and extracted with a solvent. The solvent is removed to give sufficiently pure alcohol (13) to carry forward for the next reaction.
  • Compound (13) is oxidized to give 3-halopropiophenone (14).
  • the preferred oxidizing agent is Jones reagent (Cr 2 O 3 /H 2 SO 4 ).
  • Other reagents can also conveniently be used.
  • Oxidation of (13) is carried out in solvent, preferably acetone. During the oxidation, the temperature of the reaction is maintained between 0 to 10° C.
  • 5-halo-2-nitropropiophenone (15) can be obtained by nitrating 3-halopropiophenone (14) using a nitrating agent.
  • Nitrating agent is selected from nitrating mixture of nitric acid and sulfuric acid or fuming nitric acid. Fuming nitric acid is preferred for nitration.
  • the nitration is carried out with or without solvent. During the nitration, the temperature is controlled by external cooling. The preferred temperature to carry out the nitration reaction is ⁇ 5° to 5° C. The nitration is completed within 6 to 10 hrs depending upon the batch size. At the end of nitration, the reaction solution is poured over ice or ice/water mixture and stirred to give solid.
  • the nitro compound (15) is extracted with a solvent such as DCM or chloroform and washed with water. The solvent is removed to give the desired nitro compound (15).
  • the compound (15) obtained in the above step is pure enough to carry forward
  • Compound (15) is then converted to a 5-protected or 5-unprotected propiophenone derivative.
  • the protected derivative wherein R is methyl is obtained by treating compound (14) with a suitable alkoxide.
  • R is methyl
  • the methanolic solution of a hydroxide is used. Methanolic sodium hydroxide is preferred.
  • Other hydroxides in alcohol can also be used.
  • the above reaction is carried at 0-10° C. for 2 to 5 hrs.
  • the alkaline medium is acidified to adjust the pH ⁇ 2-4 with mineral acid and the solvent is removed.
  • the extraction is carried out with a solvent, preferably DCM and organic layer, washed with water. The solvent is removed to give 5-methoxy-2-nitropropiophenone, which is sufficiently pure to take to the next step.
  • the protected derivative wherein R is ethyl is obtained by treating compound (14) with sodium hydroxide in ethyl alcohol to give 5-ethoxy-2-nitropropiophenone, using similar procedures mentioned above.
  • 5-halo-2-nitropropiophenone (15) can directly be converted to 5-hydroxy-2-nitropropiophenone (17) by heating with inorganic base in aqueous medium.
  • the 5-alkoxy compound can be smoothly converted to the corresponding phenolic compounds by deprotection on reacting with HBr, HI, Lewis acids, mercaptans, and the like by known procedures and also by heating with metal salts in suitable polar solvent.
  • suitable polar solvents are selected from DMF, DSMO, DMA or N-methyl pyrrolidine.
  • the preferred method of demethylating 5-methoxy-2-nitropropiophenone to give 5-hydroxy-2-nitropropiophenone (17) is by heating with lithium chloride in DMF at reflux temp for 2 to 10 hrs. Deprotection can also be effected with Lewis acids. Thus, the 5-ethoxy compound is deprotected using ZnCl 2 in conc. HCl.
  • Compound (17) is purified by diluting the crude mixture with water and extracting into ethyl acetate and removal of solvent. Isolation of pure 5-hydroxy-2-nitropropiophenone may require use of silica gel column chromatography.
  • the compound (17) is then converted to 2-amino-5-hydroxypropiophenone (11) by reduction of the nitro group using reducing agent.
  • the compound (17) can be reduced using various reducing agents including hydrogenation in presence of any suitable catalyst such as Raney nickel or Pd/C.
  • the preferred method of reducing compound (17) is by sodium dithionite in alkaline medium.
  • compound (17) is taken in methanol and added to a suspension of sodium dithionate and sodium carbonate in water and the reaction is best carried out at 0 to 30° C. for 2 to 5 hrs to obtain 2-amino-5-hydroxypropiophenone.
  • the 2-amino-5-hydroxypropiophenone thus obtained is purified by crystallization from suitable organic solvent.
  • Toluene is the preferred solvent for the crystallization of compound.
  • the compound thus obtained is more than 98% pure, by HPLC.
  • the 2-amino-5-hydroxypropiophenone (11), thus obtained is condensed with cyclic triketone (4) by Friedlander reaction, known in the art, in toluene in presence of acetic acid and p-toluene sulfonic acid to give SN-38.
  • the said reaction is carried out at 100° C. for 15-20 hrs.
  • the solvent is removed, reaction mass taken in acetic acid and diluted with ethanol to provide SN-38 as a colourless compound, having purity greater than 99.5%.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
US11/997,688 2005-08-03 2005-09-27 Method of synthesizing key intermediates for the production of camptothecin derivatives Expired - Lifetime US7608740B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1053CH2005 2005-08-03
IN1053/CHE/2005 2005-08-03
PCT/IN2005/000326 WO2007015259A2 (fr) 2005-08-03 2005-09-27 Procede de synthese d'intermediaires cles pour la production de derives de camptothecine

Publications (2)

Publication Number Publication Date
US20080221358A1 US20080221358A1 (en) 2008-09-11
US7608740B2 true US7608740B2 (en) 2009-10-27

Family

ID=37709010

Family Applications (1)

Application Number Title Priority Date Filing Date
US11/997,688 Expired - Lifetime US7608740B2 (en) 2005-08-03 2005-09-27 Method of synthesizing key intermediates for the production of camptothecin derivatives

Country Status (4)

Country Link
US (1) US7608740B2 (fr)
EP (1) EP1910269B1 (fr)
ES (1) ES2432553T3 (fr)
WO (1) WO2007015259A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020148641A1 (fr) * 2019-01-15 2020-07-23 Laurus Labs Limited Procédé de préparation de 2-amino-5-hydroxy propiophénone

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007015259A2 (fr) 2005-08-03 2007-02-08 Avra Laboratories Pvt. Ltd. Procede de synthese d'intermediaires cles pour la production de derives de camptothecine
WO2009002489A2 (fr) * 2007-06-25 2008-12-31 Scinopharm Taiwan Ltd. Polymorphe cristallin de 7-ethyl-10-hydroxycamptothecine

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031098A (en) 1975-02-20 1977-06-21 Shionogi & Co., Ltd. Camptothecin analogues
EP0074256A1 (fr) 1981-09-04 1983-03-16 Kabushiki Kaisha Yakult Honsha Dérivés de camptothécine, procédé pour leur préparation, compositions contenant les dérivés et leur utilisation
US4604463A (en) 1983-07-14 1986-08-05 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
US5391745A (en) 1992-07-23 1995-02-21 Sloan-Kettering Institute For Cancer Research Methods of preparation of camptothecin analogs
EP0845464A2 (fr) 1996-10-30 1998-06-03 Tanabe Seiyaku Co., Ltd. Composés d'ester de l'acide hydroxy-2-indolinybutyrique 2-substitué du type S comme intermédiaires de camptothecin
EP1378505A1 (fr) 2001-02-21 2004-01-07 Kabushiki Kaisha Yakult Honsha Procede de synthese de composes se rapportant a la camptothecine
WO2005058910A1 (fr) 2003-12-16 2005-06-30 Pliva-Lachema A.S. Procede de fabrication de 7-ethyl-10-hydroxycamptothecine
WO2007015259A2 (fr) 2005-08-03 2007-02-08 Avra Laboratories Pvt. Ltd. Procede de synthese d'intermediaires cles pour la production de derives de camptothecine

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031098A (en) 1975-02-20 1977-06-21 Shionogi & Co., Ltd. Camptothecin analogues
EP0074256A1 (fr) 1981-09-04 1983-03-16 Kabushiki Kaisha Yakult Honsha Dérivés de camptothécine, procédé pour leur préparation, compositions contenant les dérivés et leur utilisation
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
US4545880A (en) 1981-09-04 1985-10-08 Kabushiki Kaisha Yakult Honsha Photochemical process for preparing camptothecin derivatives
US4604463A (en) 1983-07-14 1986-08-05 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
US5391745A (en) 1992-07-23 1995-02-21 Sloan-Kettering Institute For Cancer Research Methods of preparation of camptothecin analogs
EP0845464A2 (fr) 1996-10-30 1998-06-03 Tanabe Seiyaku Co., Ltd. Composés d'ester de l'acide hydroxy-2-indolinybutyrique 2-substitué du type S comme intermédiaires de camptothecin
EP1378505A1 (fr) 2001-02-21 2004-01-07 Kabushiki Kaisha Yakult Honsha Procede de synthese de composes se rapportant a la camptothecine
US20040106830A1 (en) 2001-02-21 2004-06-03 Takanori Ogawa Method of synthesizing camptothecin-relating compounds
US7126000B2 (en) 2001-02-21 2006-10-24 Kabushiki Kaisha Yakult Honsha Method of synthesizing camptothecin-relating compounds
WO2005058910A1 (fr) 2003-12-16 2005-06-30 Pliva-Lachema A.S. Procede de fabrication de 7-ethyl-10-hydroxycamptothecine
WO2007015259A2 (fr) 2005-08-03 2007-02-08 Avra Laboratories Pvt. Ltd. Procede de synthese d'intermediaires cles pour la production de derives de camptothecine

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Corey et al., 1975, "A Total Synthesis of Natural 20(S)-Campthothecin", Journal of Organic Chemistry, 40 (14), 2140-41.
Henegar at al., 1997, "Practical Asymmetric Synthesis of (S)-4-Ethyl-7,8-dihydo-4-hydroxy-1H-pyrano[3,4-f]indolizine-3,6,10(4H)-trione, a Key Intermediate for the Synthesis of Irinotecan and Other Camptothecin Analogs", Journal of Organic Chemistry, 62, 6588-97.
Kametani et al. 1981, "Studies on the Syntheses of Heterocyclic Compounds, Part 878. Synthesis of (±)-Camptothecin and (±)-10-Methoxycamptothecin via Enamine Annulation", Journal of Chemical Perkin Trans,1 (5), 1563-68.
PCT International Search Report for Rao, et al., International App'l No. PCT/IN2005/000326, filed Sep. 27, 2005, Dated Nov. 13, 2007.
Perez, et al., 2001, "Microbiological Resolution of Chiral Arylethyl Carbinols by Nocardia Corallina", Biotechnology Letters, vol. 23(18):1467-1472.
Sakoh, et al., 2004, "Synthesis and Antifungal Activity of Novel 14-Membered Benzomacrolides as Galbonolide Analogues", Chemical & Pharmaceutical Bulletin, vol. 52(1):163-165.
Sawada et al., 1991, "Synthesis and Antitumor Activity of 20(S)-Camptothecin Derivatives: Carbamate-Linked, Water Soluble Derivatives of 7-Ethyl-10-hydroxycamptothecin", Chemical and Pharmaceutical Bulletin, vol. 39(6): 1446-1454.
Wani et al., 1970, "Plants Antitumour Agents: Alkaloids: Synthesis of a Pentacyclin Camptothecin Precursor", Journal of Chemistry Society, Chemical Communications, D, (7) 404.
Wani et al., 1972, "Plant Antitumor Agents, IX. The Total Synthesis of dl-Camptothecin", Journal of the American Chemical Society, 94(10), 3631-32.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020148641A1 (fr) * 2019-01-15 2020-07-23 Laurus Labs Limited Procédé de préparation de 2-amino-5-hydroxy propiophénone
US11434196B2 (en) * 2019-01-15 2022-09-06 Laurus Labs Limited Process for preparation of 2-Amino-5-hydroxy propiophenone

Also Published As

Publication number Publication date
US20080221358A1 (en) 2008-09-11
WO2007015259A3 (fr) 2008-01-03
EP1910269A2 (fr) 2008-04-16
EP1910269B1 (fr) 2013-09-18
ES2432553T3 (es) 2013-12-04
WO2007015259A2 (fr) 2007-02-08

Similar Documents

Publication Publication Date Title
US7126000B2 (en) Method of synthesizing camptothecin-relating compounds
US6864370B1 (en) Process for manufacturing oxycodone
US20230257392A1 (en) Intermediate for synthesizing camptothecin derivative, preparation method therefor, and use thereof
CN104628572B (zh) 2‑(5‑氟‑2,4‑二硝基苯氧)乙酸酯的合成方法
Zajc et al. Fluorination with xenon difluoride. 37. Room-temperature rearrangement of aryl-substituted ketones to difluoro-substituted ethers
US7608740B2 (en) Method of synthesizing key intermediates for the production of camptothecin derivatives
EP1846412B1 (fr) Procede de fabrication du camptothecine 7-ethyl-10-hydroxy
CN112876461A (zh) 尼古丁及其中间体的制备方法
US7553978B2 (en) Process for the preparation of 1-naphthol mixed ethers and intermediates of crystalline forms of (+) and (−)-duloxetine
US7662964B2 (en) Process for producing [1,4′] bipiperidinyl-1′-carbonyl chloride or hydrochloride thereof
US8466287B2 (en) Process for producing tricyclic ketone
US7109327B2 (en) Total synthesis of galanthamine, analogues and derivatives thereof
US7423152B2 (en) Process for the manufacture of intermediates in camptothecin production
US6380436B1 (en) Process for the synthesis of alkoxyalkyl (trifluormethylphenyl) methanones
EP0881207A1 (fr) Derives du 2,3-dihalogeno-6-trifluoromethylbenzene et leurs procedes de preparation
CN112300186B (zh) 六氢呋喃并呋喃醇衍生物的制备方法、其中间体及其制备方法
US20100174091A1 (en) Process for the preparation of tetrazolytetrahydrocyclopentapyrazoles
JP2003160536A (ja) フェニル酢酸エステル化合物の製造法
JPH08268974A (ja) 3−フルオロ−4−クロロ−6−ニトロベンズアルデヒド、3−フルオロ−4−クロロ−6−ニトロベンズアルデヒドアセタ−ル類及びそれらの製造方法
JPH072759A (ja) 3置換ベンゼンの製造法および中間体
WO2007108006A1 (fr) Procédé de synthèse de l'acide 6-(4-chlorophényl)-2,2-diméthyl-7-phényl-2,3-dihydro-1h-pyrrolizin-5-ylacétique et de ses intermédiaires

Legal Events

Date Code Title Description
AS Assignment

Owner name: AVRA LABORATORIES PVT. LTD., INDIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RAO, RAMAKRISHNA;ALLA, RAO VENKATA RAMA;REEL/FRAME:021237/0320

Effective date: 20080128

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2553); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 12